Successful Passing Of The EU Qualified Person Audit Of The Group’s Manufacturing Facility For ReCOV In Taizhou

TAIZHOU, China, April 11, 2022 /PRNewswire/ — The board of directors of Jiangsu Recbio Engineering Co., Ltd. (the “Organization”, with each other with its subsidiaries, the “Group”,Inventory code:2179.HK) is delighted to announce that, on April 9, 2022, the Firm has received the European Union (EU) Qualified Person Declaration issued by a Skilled Man or woman (“QP”) for the Group’s production facility for its recombinant protein COVID-19 vaccine, ReCOV (“ReCOV”) in Taizhou, the People’s Republic of China (the “PRC”).

Pursuant to Eudralex Vol 4 restrictions (EU Superior Manufacturing Apply) and the guiding concepts of Intercontinental Council for Harmonisation of Technical Requirements for Registration of Prescribed drugs for Human Use (ICH), Parenteral Drug Association (PDA) and International Modern society for Pharmaceutical Engineering (ISPE), and so forth., this EU QP audit predominantly concentrated on the bulk and planning of antigen and the novel adjuvant BFA03, masking producing administration program, top quality administration technique, production equipment and facility management procedure, validation and computerized units, content management techniques, product or service screening and launch administration and other aspects of a detailed systematic and in-depth inspection. This signifies the Group’s production facility in Taizhou and its excellent management process have achieved EU GMP expectations, laying a solid basis for the higher-good quality progress and potential global commercialisation of ReCOV.

ReCOV is a recombinant COVID-19 vaccine getting created by the Team with its technologies platforms which includes the novel adjuvant and protein engineering platforms. Based mostly on the related studies carried out by the Group, ReCOV has revealed favourable neutralizing result and immune persistence in opposition to variants together with Omicron variant and Delta variant. Scientific data from the Group’s period I demo for ReCOV in New Zealand also showed that it has an overall favorable basic safety profile and may possibly possibly induce equivalent or larger stage of neutralizing antibodies than other promoted mRNA COVID-19 vaccines and vaccine candidates.

About Recbio

Recbio is an impressive vaccine corporation founded in 2012. With the vision of “Become the Chief of Innovative Vaccine in the Long term,” Recbio will take “Protect Human Health with Finest-in-Course Vaccines” as its mission. It has proven 3 big chopping-edge engineering platforms which includes novel adjuvants system, protein engineering system, and immunological analysis system. Recbio has a high-benefit vaccine portfolio consisted of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, older people TB vaccine candidates and many others. The core administration workforce has far more than 20 a long time of encounter in the development and commercialization of modern vaccines. For far more info, you should go to https://www.recbio.cn/.

About Recombinant Two-Element COVID-19 Vaccine (ReCOV)

In May well 2020, Recbio, with each other with Jiangsu Provincial Center for Disorder Manage and Avoidance (“Jiangsu CDC”) and Taizhou Health-related New & Higher-tech Industrial Improvement Zone, jointly formulated a recombinant two-ingredient COVID-19 vaccine(ReCOV). Underneath the direction of Professor Fengcai Zhu from the Jiangsu CDC, the R&D staff extensively optimized the vaccine working with protein engineering and new adjuvant systems, so that ReCOV has promising safety and strong immunogenicity against SARS-CoV-2 and variants of problem this kind of as Omicorn and Delta. A sequence of comprehensive pros these types of as far better cross-safety against rising variants, effortless scale-up of output, charge pros, all over the world accessibility, superior preparation steadiness, and storage and transportation at area temperature which become a quite competitive second-era new COVID-19 vaccine.

Forward-Wanting Statements

This news launch could consist of specified ahead-on the lookout statements that are, by their character, subject to major challenges and uncertainties. The words “foresee”, “imagine”, “estimate”, “expect”, “intend” and comparable expressions, as they relate to Recbio, are intended to discover certain of these types of ahead-on the lookout statements. Recbio does not intend to update these forward-searching statements on a regular basis.

These forward-seeking statements are primarily based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the administration of Recbio with regard to upcoming occasions at the time these statements are produced. These statements are not a ensure of upcoming developments and are matter to challenges, uncertainties and other variables, some of which are further than Recbio’s command and are hard to forecast. For that reason, true results may well differ materially from info contained in the ahead-searching statements as a outcome of long term changes or developments in our business, Recbio’s aggressive natural environment and political, financial, lawful and social ailments.

Jiangsu Recbio Engineering Co., Ltd.

Trader Inquiry:
E-mail: [email protected]
Tel: +86-0523-86818860

Media Inquiry:
Electronic mail: [email protected]
Tel: +86-0523-86818860

Associated Inbound links:
https://www.recbio.cn/

Supply Jiangsu Recbio Know-how Co., Ltd.